Author

Lalit Kumar

View on Semantic Scholar

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Jul 2026

Gelatin Nanocarriers as Biocompatible Platforms for Targeted Drug Delivery in Cancer Therapy.

INTRODUCTION Innovative drug delivery systems are required to improve the therapeutic efficacy of cancer, which continues to be a global health challenge. Gelatin-based nanocarriers provide a prospective platform for targeted cancer therapy by utilizing their biocompatibility and stimuli-responsive properties, thereby addressing the limitations of conventional treatments. METHODS This review provides an overview of gelatin nanoparticles for the effective delivery of anticancer drugs. Various search databases were utilized for literature investigation, including PubMed, ScienceDirect, and Google Scholar. All the studies from the year 2015 to 2025 were added, along with patents associated with the field. RESULTS In lung, breast, melanoma, and other miscellaneous malignancies, gelatin nanoparticles exhibit reduced systemic toxicity and improved drug targeting. When combined with therapies, such as ultrasound or photothermal treatment, studies have demonstrated enhanced cellular absorption, sustained drug release, and synergistic effects. The increasing interest in their diagnostic and therapeutic applications is reflected in patents. DISCUSSION The improved treatment outcomes are facilitated by the versatility of gelatin nanocarriers, which allows for the tailored release of drugs in response to tumor-specific stimuli. Nevertheless, clinical implementation is impeded by obstacles, such as scalable production, nanoparticle stability, and unpredictable drug release. To surmount these obstacles, there are emerging strategies, such as stimuli-responsive and size-transformable nanoparticles. CONCLUSION The precise delivery of drugs through gelatin-based nanosystems has the potential to revolutionise cancer therapy. To ensure their successful clinical application, it is essential to address current limitations through innovative engineering and integration with advanced therapeutic modalities.

Lalit Kumar, Vikas Aggarwal, Komal Komal et al. · Anti-Cancer Agents in Medici... · 0 citations

Review Jul 2026

Pharmacological activities and mechanistic insights of justicidin variants: a multi-target natural lignans.

Justicidins are naturally occurring arylnaphthalene lignans found mainly in Justicia species, with documented anticancer, anti-inflammatory, antiviral, neuroprotective, and cardioprotective activities. They target several biochemical pathways, such as NF-κB, MAPK, and PI3K/Akt/mTOR, and have the potential to serve as multi-target drugs for complex diseases. Although there have been several in vitro and in vivo studies, most remain preclinical and isolated, with little consideration of structure-activity relationships, pharmacokinetics, and translational relevance. This review provides a pathway-centric, integrative review of justicidins, links structures to activities, pharmacokinetic and toxicological properties of analogues, and explores synergy with current drugs. We also discuss developments in analytical, biosynthetic, and formulation that might expedite drug discovery. However, key challenges include low water solubility, low bioavailability, the absence of chronic toxicity studies, and a lack of clinical trials. To overcome these challenges, it is important to focus on optimization, GMP production, chronic toxicity evaluation, and early clinical evaluation. With focused development, justicidins have the potential to go from natural products to therapeutic leads against cancer, inflammation, and viral infections.

Neeraj Choudhary, Vinod Kumar Gauttam, Dinesh Kumar et al. · Fitoterapia · 3 citations